Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

Inclusion Criteria:

• Healthy children aged 12~15 months;

• Participants' legal guardians are able to understand and sign the informed consentvoluntarily;

• Participants are able to comply with the study procedures based on the assessment ofthe investigator;

• Participants should provide verifiable identification, to be contacted, and tocontact the investigator during the study period.

Exclusion Criteria:

• Prior vaccination with any varicella containing vaccines;

• Prior history of VZV infection;

• Known allergy to vaccines or vaccine ingredients, or serious adverse reactions tovaccines, such as urticaria, dyspnea, angioneurotic edema;

• Autoimmune diseases (including but not limited to systemic lupus erythematosus,rheumatoid arthritis, etc.) or immunodeficiency/immunosuppression (such as HIVinfection, organ transplantation), asplenia;

• Receipt of blood products or immunoglobulins within the past 3 months beforeenrollment in this study, or scheduled to receive these treatments during the studyperiod;

• Receipt of other investigational vaccines within 30 days prior to vaccination inthis study;

• Receipt of attenuated live vaccines within 28 days prior to vaccination in thisstudy;

• Receipt of inactivated or subunit vaccines within 7 days prior to vaccination inthis study;

• Acute onset of various acute diseases or chronic diseases within 7 days prior tovaccination in this study;

• Has fever on the day of vaccination, with the axillary temperature >37°C beforevaccination;

• Is participating in or planning to participate in other vaccine or drug clinicaltrials;

• Any confirmed or suspected syphilis, hepatitis B or hepatitis C infection;

• According to the investigator's judgment, the subject has any other factors thatmight interfere with the clinical trial results or pose additional risk to theparticipant due to participation in the study.